Global nutraceutical contract organisation Sirio Pharma has appointed a new General Manager in Europe, named Sara Lesina.
The move is set to drive forward a strategy of small and medium brands launching novel nutraceutical formulations.
Lesina’s appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources.
Speaking about the new role, Lesina said: “I joined because I see the tremendous resources it has – Sirio has over 200 R&D scientists across its sites – and there are clear synergies with like-minded innovation focused customers. We anticipate significant growth in the nutra market in the next few years as customers see the benefits of working with an agile CDMO partner to help launch products to market faster.”
Sara brings with her a tremendous global network and what impressed us is the clarity of purpose to establish Sirio as the contract research and development hub for the most ambitious global brands.
Prior to five years at Lonza (and Capsugel) in senior executive roles, Lesina spent six years at Cargill’s food and beverages division and is widely known across the industry for her ability to identify new market opportunities and help customers tap major growth trends.
Rui Yang, VP at Sirio Pharma added: “Sara brings with her a tremendous global network and what impressed us is the clarity of purpose to establish Sirio as the contract research and development hub for the most ambitious global brands. Across Europe there is an increasing number of companies launching new products that could reduce their time to market and/or acquisition by working with Sirio. Sara’s remit will be to help develop locally relevant options, working as the European conduit to access SIRIO’s global R&D resources.”